During the venetoclax ramp-up period, DDIs with strong CYP3A4 and P-gp inhibitors can result in life-threatening complications by significantly increasing the risk of tumor lysis syndrome (TLS) and severe myelosuppression (e.g., neutropenia, thrombocytopenia, or anemia). This evidence concerns the gene CYP3A4 and Tumor Lysis Syndrome.